Business Information
The group's principal activity is the application of transgenic technology to the development and production of recombinant proteins for therapeutic and other biomedical uses. It has several partnerships with pharmaceutical and other biotechnology companies to develop monoclonal antibodies and immunoglobulin (ig) fusion proteins transgenically. The group's operations in goat husbandry, breeding, milking and clarification to intermediate bulk material occur at the company's biopharmaceutical farm production facilities in central Massachusetts. It also develops transgenic production processes for other proteins, including a malaria merozoite surface protein (msp-1) for use in a malaria vaccine. Its corporate partners include abbott, alexion, bristol-myers squibb, centocor, elan, immunogen, and progenics.
|
|
Name |
Title
|
Email
|
| Geoffrey Cox | Chmn., CEO, Pres. | N/A | | John Green | Sr. VP - Finance, CFO | N/A | | Ashley Lawton | VP - Business Development | N/A | | Carol Ziomek | VP - Development | N/A | | Daniel Woloshen | Sr. VP, General Counsel | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 6,128 | (35,345) | | 2005 | 6,626 | (29,493) | | 2006 | 4,152 | (30,112)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
